NIH consensus development statement on hydroxyurea treatment for sickle cell disease.

Otis W. Brawley, Llewellyn J. Cornelius, Linda R. Edwards, Vanessa Northington Gamble, Bettye L. Green, Charles E. Inturrisi, Andra H. James, Danielle Laraque, Magda H. Mendez, Carolyn J. Montoya, Brad H. Pollock, Lawrence Robinson, Aaron P. Scholnik, Melissa Schori

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


National Institutes of Health consensus and state-of-the-science statements are prepared by independent panels of health professionals and public representatives on the basis of (1) the results of a systematic literature review prepared under contract with the Agency for Healthcare Research and Quality (AHRQ), (2) presentations by investigators working in areas relevant to the conference questions during a 2-day public session, (3) questions and statements from conference attendees during open discussion periods that are part of the public session, and (4) closed deliberations by the panel during the remainder of the second day and morning of the third. This statement is an independent report of the panel and is not a policy statement of the NIH or the U.S. Government.The statement reflects the panel's assessment of medical knowledge available at the time the statement was written. Thus, it provides a "snapshot in time" of the state of knowledge on the conference topic. When reading the statement, keep in mind that new knowledge is inevitably accumulating through medical research.

Original languageEnglish
Pages (from-to)1-30
Number of pages30
JournalNIH consensus and state-of-the-science statements
Issue number1
StatePublished - 27 Feb 2008


Dive into the research topics of 'NIH consensus development statement on hydroxyurea treatment for sickle cell disease.'. Together they form a unique fingerprint.

Cite this